MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, announced the appointment of Bill Humphries as Chief Executive Officer. Bill’s leadership will enable MedPharm to accelerate its strategic growth following its merger with Tergus Pharma which significantly bolstered MedPharm’s scientific, clinical trial manufacturing, and commercial production capabilities.
As CEO of MedPharm, Mr. Humphries brings over 36 years of leadership and business transformation experience in the pharmaceutical and life sciences industries. Most recently he was CEO of Alcami where he spearheaded operational improvements, revenue growth, and client satisfaction. Prior to Alcami, he served as CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals. He has served as Chairman of the Board at Clearside Biomedical, Executive Chairman of Strata Skin Sciences, and a member of the Board of Directors at Alcami, Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV, and Bryn Pharmaceuticals. Mr. Humphries holds a B.A. from Bucknell University and MBA from Pepperdine University.
Also Read: Tune Therapeutics Secures $175M for Epigenome Editing
“It is a privilege to join MedPharm and the team at this important period in MedPharm’s evolution and growth aspirations,” said Bill Humphries, Chief Executive Officer of MedPharm. “I am excited to be part of this team and leverage my direct experience in the topical and transdermal space to accelerate MedPharm’s growth. I believe MedPharm is well positioned to serve clients across all channels in the topical space and we look forward to delivering incremental value for trusted existing and new clients.”
Pat Walsh, Chairman of the Board added, “Bill’s extensive leadership experience and deep understanding of the pharmaceutical industry make him the ideal leader to guide MedPharm through its next phase of growth. With his expertise and the strength of our combined organization, MedPharm is well-positioned to set new standards in topical and transdermal CDMO services.”
SOURCE: PRNewswire